Place des anticorps monoclonaux dans la prophylaxie et le traitement de la maladie aiguë et chronique du greffon contre l’hôte en 2011

Extracorporeal photopheresis: a useful therapy for patients with steroid-refractory acute graft-versus-host disease but not for the prevention of the chronic form

“…This is considered to be the standard first‐line systemic therapy for moderate to severe aGVHD, resulting in complete response rates of 25–54%. Patients not responding to steroids have mortality rates as high as 95% . Combining other immunosuppressants with corticosteroids has not improved response rates or overall survival of patients with aGVHD and is therefore not considered standard care.…”

“…Patients not responding to steroids have mortality rates as high as 95%. 3,7 Combining other immunosuppressants with corticosteroids has not improved response rates or overall survival of patients with aGVHD and is therefore not considered standard care. Approaches using monoclonal antibodies against cytokines or other molecules involved in GVHD pathogenesis have brought little progress in the treatment of this disease.…”